ArticleScience (New York, N.Y.)2016
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.
2 registry-linked trialsAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 869 papers.
0numbers the graph read from it
0cells of the map it votes in
869citing papers in PubMed
47.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT03941496 phase1 / phase2withdrawnnot on this mapstarted 2022, after this paper: background citation
Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy
Biomarker Driven Phase 1/1b Trial of Decitabine and Nivolumab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Who cites it
869 citing papers in PubMed, 1,253 citations in OpenAlex.
- Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.Nature communications · 2026Trial
- Cancer metastasis: biological mechanisms, therapeutic bottlenecks, and emerging interventions.Journal of hematology & oncology · 2026Review
- Latent effector capacity governs reversible T cell exhaustion: A theoretical mathematical model of PD-1 blockade response.Science advances · 2026Article
- Targeting myeloid cell plasticity and metabolic reprogramming to alleviate T cell dysfunction and exhaustion-associated states and enhance immune checkpoint blockade therapy.Biomarker research · 2026Review
- Tumor-Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy-Immunotherapy Combination Trials.International journal of cancer · 2026Review
- LAG3 checkpoint function and its mechanism of action in therapeutic targeting.Nature reviews. Immunology · 2026Review
- In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy.Cancer immunology research · 2026Article
- A multitargeting nanoparticle-based vaccine for enhanced anticancer immunotherapy in HER2-Positive breast cancer.Materials today. Bio · 2026Article
- Overcoming T cell exhaustion and senescence in CAR T cell therapy for solid tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review).International journal of oncology · 2026Review
- ANKRD11 deficiency reprograms CD8Nature immunology · 2026Article
- Spatial and Single-Cell Multi-Omics Analyses of T-Cell Subsets and Interactions in Melanoma Lymph Node Metastasis.Experimental dermatology · 2026Review
- CD39 on CD8European journal of immunology · 2026Review
- Multi-omics integration identifies PON2 as a prognostic biomarker and mediator of tumor microenvironment remodeling in gallbladder cancer.Translational cancer research · 2026Article
- High ZFP36 Family Expression in Exhausted T Cells Is Associated With Impaired Antitumor Effector Function.Cancer science · 2026Article
- Article
- Short-chain fatty acids act as metabolic and epigenetic regulators in CAR T cell therapy.Molecular therapy. Oncology · 2026Review
- Impaired regulation by purinergic signaling axis contributes to CD8+ T cell dysregulation in STAT3 gain of function.JCI insight · 2026Article
- Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases.Stem cell research & therapy · 2026Review
- T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy.Signal transduction and targeted therapy · 2026Review
809 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
19 authors at 3 institutions in 1 country.
Kristen E PaukenDepartment of Microbiology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Morgan A SammonsDepartments of Cell and Developmental Biology, Genetics, and Biology, Penn Epigenetics Program, University of Pennsylvania, Philadelphia, PA, USA.
Pamela M OdorizziDepartment of Microbiology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Sasikanth ManneDepartment of Microbiology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jernej GodecDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Omar KhanDepartment of Microbiology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Adam M DrakeDepartments of Cell and Developmental Biology, Genetics, and Biology, Penn Epigenetics Program, University of Pennsylvania, Philadelphia, PA, USA.
Zeyu ChenDepartment of Microbiology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Debattama R SenDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Makoto KurachiDepartment of Microbiology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
R Anthony BarnitzDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Caroline BartmanDepartment of Microbiology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Bertram BengschDepartment of Microbiology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Alexander C HuangDepartment of Medicine and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jason M SchenkelDepartment of Microbiology and Immunology, University of Minnesota, Minneapolis, MN, USA.
Golnaz VahediDepartment of Genetics and Institute for Immunology, University of Pennsylvania, Philadelphia, PA, USA.
W Nicholas HainingDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shelley L BergerDepartments of Cell and Developmental Biology, Genetics, and Biology, Penn Epigenetics Program, University of Pennsylvania, Philadelphia, PA, USA.
E John WherryDepartment of Microbiology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. wherry@mail.med.upenn.edu.
University of Pennsylvania · USDana-Farber Cancer Institute · USUniversity of Minnesota · US
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3MVirology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG, GEORG Michael LAUER · 2009 to 2026
$48.1MSynergies among inhibitory receptors in tolerance, cancer & antiviral immunityP01AI108545 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Dario AA Vignali · 2015 to 2026
$30.8MSequencing and Viral Evolution CoreU19AI117950 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WHERRY, E. JOHN · 2015 to 2019
$12.0MCANCER RESEARCH TRAINING PROGRAMT32CA009615 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Gregory L Beatty, MICHAEL D HOGARTY · 1988 to 2026
$10.4MP3: Chemokine-Mediated T Cell Trafficking in HIV Transmission and Immune ResponseP01AI112521 · NIAID · HARVARD MEDICAL SCHOOL · PI VON ANDRIAN, ULRICH H · 2014 to 2018
$9.8MRole of PCAF/GCN5 Acetylation on p53 TransactivationR01CA078831 · NCI · WISTAR INSTITUTE · PI BERGER, SHELLEY L · 1999 to 2022
$7.8MTesting the role of BATF as a pioneer transcription factor in effector T cellsR01AI115712 · NIAID · DANA-FARBER CANCER INST · PI KADOCH, CIGALL, WHERRY, E. JOHN · 2015 to 2019
$2.9MRegulation of exhaustion and altered CD8 T cell memory during chronic InfectionR01AI071309 · NIAID · WISTAR INSTITUTE · PI WHERRY, E. JOHN · 2006 to 2010
$1.8MCellular and transcriptional control of exhausted CD8 T cells lineage dynamicsR01AI105343 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WHERRY, E. JOHN · 2014 to 2017
$1.6MTrafficking & role of effector memory CD8T cell subsets in small intestineF30DK100159 · NIDDK · UNIVERSITY OF MINNESOTA · PI SCHENKEL, JASON M. · 2013 to 2015
$100kNCI NIH HHS P30 CA016520NCI NIH HHS R01 CA078831NCI NIH HHS T32 CA009615NIAID NIH HHS P01 AI108545NIAID NIH HHS P01 AI112521NIAID NIH HHS R01 AI071309NIAID NIH HHS R01 AI105343NIAID NIH HHS R01 AI115712NIAID NIH HHS U19 AI082630NIAID NIH HHS U19 AI117950NIDDK NIH HHS F30 DK100159
Abstract
Blocking Programmed Death-1 (PD-1) can reinvigorate exhausted CD8 T cells (T
Indexed as
Epigenesis, GeneticAnimalsB7-H1 AntigenCD8-Positive T-LymphocytesCell LineageCellular ReprogrammingFemaleGene Regulatory NetworksImmunologic MemoryImmunotherapyInterleukin-7MiceMice, Inbred C57BLTranscription, GeneticB7-H1 AntigenInterleukin-7
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03941496ClinicalTrials.gov
NCT07216833ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.